Effect of Anti CD20 in Pemphigus Desease

Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00213512

Enrollment

Registered

2005-09-21

Start date

2003-06-30

Completion date

2008-10-31

Last updated

2013-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus

Brief summary

to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.

Interventions

DRUGMabthera

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age\>18 * pemphigus corticoresistant * pemphigus cortico dependant * contre-indications : systémic steroids

Exclusion criteria

* age \< 18 * cardiopathie * pregnant woman * absence contraception * no consentment

Design outcomes

Primary

Measure	Time frame
primary end-point was the rate of CR three months after the last infusion of Rituximab	—

Secondary

Measure	Time frame
secondary end-points were :	—
rate of CR during the study period	—
time from the start of Rituximab to CR	—
number and length of time to relapses	—
treatment tolerance	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026